Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon.
The cardiovascular, renal, pulmonary, and dermatologic toxicities of interleukin-2 (IL-2) and gamma-interferon (IFN) are well described. However, autoimmune toxicities have only recently been noticed. The authors report the development of warm autoantibodies against erythrocytes in a patient receiving IL-2 (3.75 x 10(6) cetus units/m2 intravenous bolus three times per week) and gamma-IFN (0.1 mg/m2 subcutaneously three times per week) for metastatic renal cell carcinoma. Other potential causes of autoantibody formation, such as drugs, infection, and collagen vascular disease, were excluded. Both gamma-IFN and IL-2 have the potential to trigger or exacerbate autoimmunity due to either aberrant expression of restricted antigens or inhibition of normal cellular immune suppressor mechanisms.
Perez
R
R
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.
Padavic
K
K
Krigel
R
R
Weiner
L
L
D001323:Autoantibodies / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000556:secondary / Q000628:therapy*; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000276:immunology* / Q000628:therapy*; D008875:Middle Aged
D001323:Autoantibodies; D007376:Interleukin-2; D007371:Interferon-gamma